Tybost (Cobicistat) Patent Expiration, LOE Window & CMS Spending

Tybost (Cobicistat) by Gilead Sciences: FDA Orange Book core substance LOE 2030-03-03 (last listed 2033-04-06), 0 AB generics, $369K 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN203094 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-03-03
Last Listed Patent or Exclusivity Date2033-04-06
Orange Book Patents (*PED Extensions)4 patents (2 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$369K
2024 Medicare Part D Spend$270K
2024 Medicaid Spend$99K
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 17.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.